Profiles

Keywords
Last Name
Institution

Jennifer Goldman

TitleAssociate Professor
InstitutionRush University, Rush Medical College
DepartmentNeurological Sciences
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 7401759793.
    My NIH COMMONS name is JGOLDMAN1.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B. Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimers Res Ther. 2019 Mar 13; 11(1):23. PMID: 30867052.
      View in: PubMed
    2. Zhong Z, Merkitch D, Karaman MM, Zhang J, Sui Y, Goldman JG, Zhou XJ. High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra. Radiology. 2019 Apr; 291(1):149-157. PMID: 30777809.
      View in: PubMed
    3. Hoogland J, Boel JA, de Bie RMA, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ. Risk of Parkinson's disease dementia related to level I MDS PD-MCI. Mov Disord. 2019 Mar; 34(3):430-435. PMID: 30653248.
      View in: PubMed
    4. Purcell NL, Goldman JG, Ouyang B, Bernard B, O'Keefe JA. The Effects of Dual-Task Cognitive Interference and Environmental Challenges on Balance in Huntington's Disease. Mov Disord Clin Pract. 2019 Mar; 6(3):202-212. PMID: 30949551.
      View in: PubMed
    5. Bledsoe IO, Stebbins GT, Merkitch D, Goldman JG. White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease. Neurology. 2018 Dec 11; 91(24):e2244-e2255. PMID: 30429273.
      View in: PubMed
    6. Holden SK, Medina LD, Hoyt B, Sillau SH, Berman BD, Goldman JG, Weintraub D, Kluger BM. Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. Mov Disord. 2018 Nov; 33(11):1760-1768. PMID: 30306618.
      View in: PubMed
    7. Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D. Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. Mov Disord. 2018 Nov; 33(11):1750-1759. PMID: 30216541.
      View in: PubMed
    8. Kang UJ, Taylor P, Naito A, Goldman JG. Reply To: Detection of Alpha-Synuclein in Saliva: The Importance of Preanalytical Assessment. Mov Disord. 2018 07; 33(6):1031. PMID: 30134056.
      View in: PubMed
    9. Goldman JG, Vernaleo BA, Camicioli R, Dahodwala N, Dobkin RD, Ellis T, Galvin JE, Marras C, Edwards J, Fields J, Golden R, Karlawish J, Levin B, Shulman L, Smith G, Tangney C, Thomas CA, Tröster AI, Uc EY, Coyan N, Ellman C, Ellman M, Hoffman C, Hoffman S, Simmonds D. Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. NPJ Parkinsons Dis. 2018; 4:19. PMID: 29951580.
      View in: PubMed
    10. Antoon JW, Goldman JL, Shah SS, Lee B. A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. J Allergy Clin Immunol Pract. 2019 Jan; 7(1):244-250.e1. PMID: 29859332.
      View in: PubMed
    11. Siderowf A, Aarsland D, Mollenhauer B, Goldman JG, Ravina B. Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. Mov Disord. 2018 04; 33(4):528-536. PMID: 29624752.
      View in: PubMed
    12. Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP. Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. Mov Disord. 2018 04; 33(4):503-510. PMID: 29488270.
      View in: PubMed
    13. Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P. Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Mov Disord. 2018 03; 33(3):499-500. PMID: 29460975.
      View in: PubMed
    14. Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol. 2018 Mar; 35(2):182-187. PMID: 29315761.
      View in: PubMed
    15. Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Saint-Hilaire MH, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018 02; 33(2):282-288. PMID: 29205509.
      View in: PubMed
    16. Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2018 02; 33(2):208-218. PMID: 29168899.
      View in: PubMed
    17. Hoogland J, Boel JA, de Bie RMA, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ. Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Mov Disord. 2017 Jul; 32(7):1056-1065. PMID: 28605056.
      View in: PubMed
    18. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 04; 89(1):88-100. PMID: 28592453.
      View in: PubMed
    19. Bailey M, Goldman JG. Characterizing Cognitive Impairment in Parkinson's Disease. Semin Neurol. 2017 04; 37(2):167-175. PMID: 28511257.
      View in: PubMed
    20. Goldman JG, Bledsoe IO, Merkitch D, Dinh V, Bernard B, Stebbins GT. Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. Neurology. 2017 Mar 28; 88(13):1265-1272. PMID: 28235816.
      View in: PubMed
    21. Yu D, Stach L, Newland JG, Selvarangan R, Goldman J. Integrating a Rapid Diagnostic Test and Antimicrobial Stewardship: Optimizing Discharge Antibiotics in Skin and Soft Tissue Infections. Pediatr Infect Dis J. 2016 12; 35(12):1362-1364. PMID: 27649364.
      View in: PubMed
    22. Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol. 2016 Oct 01; 73(10):1217-1224. PMID: 27571329.
      View in: PubMed
    23. Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP. Arguing against the proposed definition changes of PD. Mov Disord. 2016 Nov; 31(11):1619-1622. PMID: 27492190.
      View in: PubMed
    24. Guella I, Evans DM, Szu-Tu C, Nosova E, Bortnick SF. a-synuclein genetic variability: A biomarker for dementia in Parkinson disease. Ann Neurol. 2016 Jun; 79(6):991-9. PMID: 27091628.
      View in: PubMed
    25. Kang UJ, Goldman JG, Alcalay RN, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara AW, Frank S, Rudolph A, Casaceli C, Andrews H, Gwinn K, Sutherland M, Kopil C, Vincent L, Frasier M. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord. 2016 06; 31(6):924-32. PMID: 27113479.
      View in: PubMed
    26. Diederich NJ, Goldman JG, Stebbins GT, Goetz CG. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):11-22. PMID: 26650182.
      View in: PubMed
    27. Goldman JG, Aggarwal NT, Schroeder CD. Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. Neurodegener Dis Manag. 2015 Oct; 5(5):425-43. PMID: 26517759.
      View in: PubMed
    28. Goldman JG. Writer's cramp. Toxicon. 2015 Dec 01; 107(Pt A):98-104. PMID: 26391286.
      View in: PubMed
    29. Goldman JG, Weintraub D. Advances in the treatment of cognitive impairment in Parkinson's disease. Mov Disord. 2015 Sep 15; 30(11):1471-89. PMID: 26297863.
      View in: PubMed
    30. Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):95-102. PMID: 26296077.
      View in: PubMed
    31. David FJ, Robichaud JA, Leurgans SE, Poon C, Kohrt WM, Goldman JG, Comella CL, Vaillancourt DE, Corcos DM. Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. Mov Disord. 2015 Oct; 30(12):1657-63. PMID: 26148003.
      View in: PubMed
    32. Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP. Cognitive profile of LRRK2-related Parkinson's disease. Mov Disord. 2015 Apr 15; 30(5):728-33. PMID: 25650144.
      View in: PubMed
    33. Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6. PMID: 25449653.
      View in: PubMed
    34. Goldman JG, Stebbins GT, Leung V, Tilley BC, Goetz CG. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9. PMID: 25150770.
      View in: PubMed
    35. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol. 2014 Aug; 27(4):434-41. PMID: 24978368.
      View in: PubMed
    36. Neely KA, Kurani AS, Shukla P, Planetta PJ, Wagle Shukla A, Goldman JG, Corcos DM, Okun MS, Vaillancourt DE. Functional Brain Activity Relates to 0-3 and 3-8 Hz Force Oscillations in Essential Tremor. Cereb Cortex. 2015 Nov; 25(11):4191-202. PMID: 24962992.
      View in: PubMed
    37. Barton BR, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord. 2014 Sep; 29(10):1252-7. PMID: 24821679.
      View in: PubMed
    38. Chu Y, Goldman JG, Kelly L, He Y, Waliczek T, Kordower JH. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14. PMID: 24825319.
      View in: PubMed
    39. Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord. 2014 Apr 15; 29(5):608-21. PMID: 24757110.
      View in: PubMed
    40. Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol. 2014 Mar; 16(3):281. PMID: 24464490.
      View in: PubMed
    41. Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar; 137(Pt 3):849-59. PMID: 24480486.
      View in: PubMed
    42. Eberling J, Vincent L, Goldman JG, Weintraub D, Kulisevsky J, Marras C, Stebbins G, Kieburtz K. Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. J Parkinsons Dis. 2014; 4(4):585-9. PMID: 24989876.
      View in: PubMed
    43. Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Tröster AI, Burn DJ, Litvan I. Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis. 2014; 4(2):131-7. PMID: 24296865.
      View in: PubMed
    44. Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9. PMID: 24123267.
      View in: PubMed
    45. Goetz CG, Vaughan CL, Goldman JG, Stebbins GT. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014 Jan; 29(1):115-7. PMID: 23843193.
      View in: PubMed
    46. Goldman JG, Ghode RA, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord. 2013 Sep; 19(9):806-11. PMID: 23735187.
      View in: PubMed
    47. Goldman JG, Eichenseer SR, Berry-Kravis E, Zimnowodzki S, Gregory A, Hogarth P, Hayflick SJ. Clinical features of neurodegeneration with brain iron accumulation due to a C19orf12 gene mutation. Mov Disord. 2013 Sep; 28(10):1462-3. PMID: 23494994.
      View in: PubMed
    48. Hogarth P, Gregory A, Kruer MC, Sanford L, Wagoner W, Natowicz MR, Egel RT, Subramony SH, Goldman JG, Berry-Kravis E, Foulds NC, Hammans SR, Desguerre I, Rodriguez D, Wilson C, Diedrich A, Green S, Tran H, Reese L, Woltjer RL, Hayflick SJ. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology. 2013 Jan 15; 80(3):268-75. PMID: 23269600.
      View in: PubMed
    49. Kapur SS, Goldman JG. Spinocerebellar ataxia types 2 and 10: more than a coincidental association?-Reply. Arch Neurol. 2012 Nov 01; 69(11):1524-5. PMID: 23753686.
      View in: PubMed
    50. Kapur SS, Goldman JG. Two in one: report of a patient with spinocerebellar ataxia types 2 and 10. Arch Neurol. 2012 Sep; 69(9):1200-3. PMID: 22964913.
      View in: PubMed
    51. Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug; 27(9):1129-36. PMID: 22778009.
      View in: PubMed
    52. Goldman JG, Stebbins GT, Bernard B, Stoub TR, Goetz CG, deToledo-Morrell L. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord. 2012 May; 27(6):727-34. PMID: 22410753.
      View in: PubMed
    53. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012 Mar; 27(3):349-56. PMID: 22275317.
      View in: PubMed
    54. Barton B, Grabli D, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord. 2012 Feb; 27(2):248-53. PMID: 22162144.
      View in: PubMed
    55. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Tröster AI, Weintraub D. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011 Aug 15; 26(10):1814-24. PMID: 21661055.
      View in: PubMed
    56. Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011 Sep; 12(13):2009-24. PMID: 21635198.
      View in: PubMed
    57. Poon C, Robichaud JA, Corcos DM, Goldman JG, Vaillancourt DE. Combined measures of movement and force variability distinguish Parkinson's disease from essential tremor. Clin Neurophysiol. 2011 Nov; 122(11):2268-75. PMID: 21570904.
      View in: PubMed
    58. Goldman JG, Marr D, Zhou L, Ouyang B, Leurgans SE, Berry-Kravis E, Goetz CG. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2. PMID: 21506165.
      View in: PubMed
    59. Goldman JG. New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis. 2011 Mar 02; 2011:675630. PMID: 21403865.
      View in: PubMed
    60. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord. 2010 Nov 15; 25(15):2501-7. PMID: 20878991.
      View in: PubMed
    61. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008 Nov 15; 23(15):2248-50. PMID: 18823039.
      View in: PubMed
    62. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15; 22(12):1689-707; quiz 1837. PMID: 17542011.
      View in: PubMed
    63. Goldman JG, Goetz CG. History of Parkinson's disease. Handb Clin Neurol. 2007; 83:107-28. PMID: 18808912.
      View in: PubMed
    64. Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4. PMID: 15313848.
      View in: PubMed
    65. Goldman JG, Comella CL. Treatment of dystonia. Clin Neuropharmacol. 2003 Mar-Apr; 26(2):102-8. PMID: 12671530.
      View in: PubMed
    Goldman's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (174) concept(s)
    _
    Co-Authors Expand Description
    See all (15) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department